Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of...

Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as...

In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing...

A team of investigators studied Clostridioides difficile infection (CDI) isolates to gauge resistance in the 2...

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of...

Companies say the 3 doses of their vaccine meet all immunobridging criteria required for the Emergency Use Authorization...

Mashup Score:1

Contagion Live

Investigators sought information on how the infection is treated in outpatient...

A health system piloted a program that explored having an infectious disease pharmacist aid in guiding...

In a poster presented at MAD-ID 2022, Glenn S. Tillotson, PhD, FIDSA, FCCP, shares data from the Premier Healthcare Database on more than 100,000...

  • 1528381425535397889 Profile photo of Madelyn

    Catch up on all the poster data from #MADID2022 here! Here's one from @glenn_tillotson that look at the impact of #CDiff on all-cause inpatient mortality, rehospitalizations, and hospitalization cost https://t.co/pNB5kbBiro - view on twitter

Designing a transitions of care stewardship program and engaging all stakeholders can help cut down on unnecessary antibiotic...

  • 1528376389308661761 Profile photo of Madelyn

    .@n_mercuro explains how to build and implement a transitions of care #AntimicrobialStewardship program to help cut down on unnecessary prescribing at hospital discharge #MADID2022 https://t.co/4MSacjCb56 - view on twitter